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Abstract
A treatment for a complicated disease may be helpful for some but not all patients,
which makes predicting the treatment effect for new patients important yet challenging.
Here we develop a method for predicting the treatment effect based on patient char-
acteristics and use it for predicting the effect of the only drug (Riluzole) approved for
treating Amyotrophic Lateral Sclerosis (ALS). Our proposed method of model-based ran-
dom forests detects similarities in the treatment effect among patients and on this basis
computes personalised models for new patients. The entire procedure focuses on a base
model, which usually contains the treatment indicator as a single covariate and takes the
survival time or a health or treatment success measurement as primary outcome. This
base model is used both to grow the model-based trees within the forest, in which the
patient characteristics that interact with the treatment are split variables, and to com-
pute the personalised models, in which the similarity measurements enter as weights. We
applied the personalised models using data from several clinical trials for ALS from the
PRO-ACT database. Our results indicate that some ALS patients benefit more from the
drug Riluzole than others. Our method allows shifting from stratified medicine to person-
alised medicine and can also be used in assessing the treatment effect for other diseases
studied in a clinical trial.
Keywords: Personalised medicine, random forest, treatment effect, model-based recursive par-
titioning.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a deadly disease that affects motor neurons in the brain
and spinal cord, i.e. the neurons responsible for voluntary muscle control. Riluzole (Rilutek) is
the only approved drug for this disease to date. According to the European Medicines Agency
(2012), Riluzole prolongs the median survival of ALS patients, depending on the dose, by a
few months. Several side effects, such as sickness, weakness or increased liver enzyme levels
are mentioned (European Medicines Agency 2012). Knowledge how Riluzole works on the
nervous system of ALS patients is limited. The PRO-ACT database (Atassi et al. 2014) is
the largest database containing clinical trial data of ALS patients available and was initiated
to retrieve more information on the disease. It contains data from 17 ALS studies conducted
between 1990 and 2010. Using these data, we aimed at finding out more about the effect of
Riluzole on the health and survival of patients.
Before statistical analysis and p-values entered into medical progress, doctors treated patients
individually based on their experiences and knowledge (Weisberg 2015). Since the beginning
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2 Individual Treatment Effect Prediction for ALS Patients
of the “golden age of randomised clinical trials”, however, medication became more and more
standardised. Nowadays, much knowledge about the effect of drugs has accumulated, corner-
stone drugs such as antibiotics have been used for decades and many diseases can be treated
successfully; however, providing new drugs for the general public is more difficult. Diseases
such as ALS are too complex to treat all patients in the same way. Therefore, there is a need
to return to more individualised treatments, but this time with the use of statistical concepts.
In the past years, there has been an immense effort towards personalised medicine in the
analysis of randomised controlled trials. The goal is to identify predictive factors, i.e. factors
that interact with the treatment (Italiano 2011), such as biomarkers, other treatments, and
environmental circumstances. In the following, we will refer to these factors as patient char-
acteristics. Prognostic factors, i.e. factors that directly affect the patient’s outcome, are only
of secondary interest, but should not be neglected, because they not only change the general
level of the outcome – showing in the individual intercept – but might also be predictive and
prognostic (Seibold et al. 2015). For drugs for which the biological mode of action is un-
known, predictive and prognostic factors should first be identified in a data-driven way. New
hypotheses can then be generated and new trials can be planned based on these hypotheses.
In this first step we are asking whether a certain patient characteristic is relevant and not
why.
Many new statistical methods in the field of stratified medicine, i.e. subgroup analysis, have
been developed. Subgroup analyses aim at finding groups of patients that have differential
treatment effects. Most of the methods are based on recursive partitioning (trees) and/or
interaction models (Ciampi et al. 1995; Kehl and Ulm 2006; Dusseldorp and Van Mechelen
2013; Loh et al. 2015; Tian et al. 2014; Foster et al. 2015; Zhang et al. 2012). The tree meth-
ods for subgroup analyses have specialised splitting procedures for partitioning the patients
into groups with higher and lower treatment effect. Interaction models evaluate the interac-
tion between the treatment and given patient characteristics. The idea behind methods of
subgroup analyses in general is to obtain a treatment effect β(z) that depends on the patient
characteristics z. For example, the treatment effect could depend on the age of patients, in
which patients less than 40 years of age improve through the treatment, patients between 40
and 60 do not improve and patients older than 60 years improve, but less than the patients
under 40 years:
β(z) =

1 if zage < 40
0 if 40 ≤ zage < 60
0.5 if 60 ≤ zage
(1)
However, the assumption that the treatment effect is a step function may be too restrictive,
and β(z) in reality may be a smooth interaction function. In other words, personalised
medicine is required instead of stratified medicine. Because methods for subgroup analyses
again generalise the treatment effect for a group of patients, it can only be considered as a step
in the direction toward personalised medicine. We provide a method that can estimate smooth
treatment effect functions using model-based random forests and weighted models. More
importantly, this method provides an estimate for the treatment effect of a future patient,
thereby allowing a decision to be made whether treatment of this patient is appropriate.
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2. Methods
Seibold et al. (2015) introduced a means of conducting subgroup analysis using model-based
recursive partitioning. One first defines a model M((Y,X),ϑ) with primary endpoint Y ,
covariates X including the treatment indicator
XA =
{
1 if patient received the (new) treatment
0 if patient received no treatment (or standard of care),
(2)
and parameter vector ϑ. In the following we will consider likelihood models (e.g. generalised
linear models or parametric survival models) where the model parameters ϑ can be estimated
by maximising the log-likelihood l((Y,X),ϑ) of those models (e.g. Gaussian log-likelihood or
Weibull log-likelihood) or equivalently by solving the score equation
N∑
i=1
s((y,x)i,ϑ) = 0 (3)
with
s((y,x)i,ϑ) =
∂l((y,x)i,ϑ)
∂ϑ
. (4)
In most applications the model contains only an intercept α and a treatment effect β, i.e.
X = (1, XA) and ϑ = (α, β)
> but more parameters are possible, such as coefficients of
additional regressors or scale and shape parameters for the response distribution. Technically,
there can also be more than two treatment groups. For simplicity, we will focus on the simple
case with intercept and treatment effect and two treatment groups. The method obtains
subgroups {Bb=1,...,B} that differ with regard to the treatment effect β and potentially the
intercept α. The subgroups are defined by patient characteristics Z = (Z1, . . . , ZJ) ∈ Z.
Hence the intercept and treatment parameters can be written as a function of the patient
characteristics z.
Conceptually, the partitioned model parameters α(z) and β(z) might depend on z in a more
complex way than a simple tree structure. Therefore, the model parameters are not step
functions, but rather smooth interaction functions, so that an individual treatment effect (as
in personalised medicine) can be computed for each patient instead of only for each subgroup
of patients (as in stratified medicine). The function β(z) can then be understood as an
estimate of the individual treatment effect of a patient with patient characteristics z.
The most intuitive step from a tree structure to a more complex structure is to use a random
forest instead of a single tree. Hence we propose a model-based random forest for person-
alised medicine, which can be used to predict the treatment effect of future patients using
personalised models.
2.1. Random forest
Random forests (Breiman 2001) compute an ensemble of T trees. The proposed algorithm
draws subsamples Lt, t = 1, . . . , T of the given N observations and fits a model-based tree
to each subsample using a randomly sampled set of candidate split variables z. The data Lct
that were not in the learning sample for tree t are called out-of-bag data.
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Split procedure
The special feature of our method is the split procedure, which is based on the empirical
estimating function
s =

sαˆ((y,x)1, ϑˆ) sβˆ((y,x)1, ϑˆ)
sαˆ((y,x)2, ϑˆ) sβˆ((y,x)2, ϑˆ)
...
...
sαˆ((y,x)N , ϑˆ) sβˆ((y,x)N , ϑˆ)
 (5)
which contains the score contributions sαˆ((y,x)i, ϑˆ) and sβˆ((y,x)i, ϑˆ). The score contri-
butions are the partial derivatives of the log-likelihood with respect to α or β respectively
evaluated at the N observed data points and the estimated parameters ϑˆ = (αˆ, βˆ)>(Zeileis
et al. 2008). The matrix of score contributions contains information on the deviation from
the model fit for all parameters and observations of a given modelM((Y,X),ϑ). The contri-
butions can thus be seen as residuals.
To obtain a split in model-based recursive partitioning for this setup the following steps have
to be performed:
• Compute the prespecified (parametric) model M((Y,X),ϑ).
• Compute the associated score matrix s.
• Perform tests of independence between the residuals (partial score vectors) and the
partitioning variables:
Hα,j0 : sαˆ((Y,X), ϑˆ) ⊥ Zj
Hβ,j0 : sβˆ((Y,X), ϑˆ) ⊥ Zj j = 1, . . . , J
The smallest p-value corresponds to the greatest deviation from the model assump-
tion, that intercept and treatment parameter are the same for all patients in the given
node/subgroup.
• If any p-value is lower than the significance level, select the partitioning variable that
has the highest association (lowest p-value) to any of the relevant residuals for the split.
• Search for the optimal split point in the selected partitioning variable using a suitable
criterion, such that the models in the resulting daughter-nodes have as little association
between the partitioning variable and the residuals as possible.
This split procedure is repeated until a stop criterion is met. This can be, for example, when
no p-values are lower than the significance level or if subgroups become too small. In the end
a tree is obtained with disjoint subgroups
•⋃
b
Bb = Z (6)
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or a random forest with T trees and disjoint subgroups for each tree
•⋃
b
Btb = Z ∀t = 1, . . . , T. (7)
The independence tests can be performed using permutation tests (Hothorn et al. 2006a,b)
or, for reasonably large samples, using M-fluctuation tests (Zeileis and Hornik 2007; Zeileis
et al. 2008). Note that multiplicity adjustment, e.g. Bonferroni correction, is recommended.
More details on the algorithm and the test procedures used are documented in the appendix.
2.2. Personalised models
In personalised medicine, the goal is to learn how much a person will profit from a given
treatment and what would happen if the standard of care or no treatment is given. For
any patient, it is possible to compute a personalised model based on the similarity of this
observation to the observations in the training data. The similarity wi(z) of a patient i to
any patient from the training set is given as the number of times the patients are classified in
the same subgroup by the single trees in the random forest
wi(z) =
T∑
t=1
Bt∑
b=1
(zi ∈ Btb) ∧ (z ∈ Btb), (8)
with T being the number of trees used for the computation of the forest and Bt being the
number of subgroups from tree t (Hothorn et al. 2004; Meinshausen 2006). If patient i is part
of the training set, the weights can be computed out-of-bag, i.e. the only trees (t = 1, . . . , T )
considered are those where patient i is not in the subset Lt for the computation.
To obtain the personalised model for patient i the base model is recomputed with the weighted
training data or equivalently by using the weighted score function in the score equation
N∑
k=1
wi(zk) · s((y,x)i,ϑ(zi)) = 0. (9)
In other words every patient k from the training set is included wi(zk) times in the “new
data set” to compute the personalised model for patient i. In the following the parameters
estimated from this model will be denoted by ϑˆ(zi) = (αˆ(zi), βˆ(zi), . . . ).
Using the personalised models it is possible to obtain a log-likelihood. From the personalised
model for patient i, the log-likelihood contribution l((y,x)i, ϑˆ(zi)) for this observation is
computed. The log-likelihood then is
N∑
i=1
l
(
(y,x)i, ϑˆ(zi)
)
, (10)
which we refer to as forest log-likelihood.
2.3. Improvement through personalised models
To check whether the personalised models actually lead to an improvement of the base model
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we test the hypothesis
H0 :
α(Z) ≡ α︸ ︷︷ ︸
Hα0
(11)
⋂
β(Z) ≡ β︸ ︷︷ ︸
Hβ0
. (12)
This strict null hypothesis is to be rejected, if any of the patient characteristics contain
information on the outcome or the treatment effect. To conduct the test, one can proceed as
follows:
• Compute the forest log-likelihood and the log-likelihood of the base model and calculate
their difference.
• Draw parametric bootstrap samples from the base model.
• Compute the forest log-likelihood and the log-likelihood of the base model in the boot-
strap samples and again compute the differences.
• The p-value is then the proportion of bootstrap samples in which the difference in log-
likelihoods exceeds the observed difference in the original data. Note, that this p-value
will be very low or even zero when the patient characteristics contain information on
the outcome or the treatment effect.
In practice, one may be interested in just Hβ0 , but testing the sub-hypotheses H
α
0 and H
β
0
separately is not straight forward. An approximation would be to compute the personalised
models using a forest that splits only based on the partial score function with respect to
α or β respectively. Patient characteristics, however, are often not exclusively predictive or
prognostic but may be both. Also, if a patient characteristic is purely prognostic, this still
may result in a pattern in both partial score functions. For more details, see Seibold et al.
(2015).
2.4. Dependence plots
A partial dependence plot describes the dependence of a function (in our case the treatment
effect βˆ(z)) and a variable (in our case a partitioning variable) (Hastie et al. 2009). The partial
dependence plot resulting from a model-based tree would show a step function. The partial
dependence from a random forest can be smoother for continuous partitioning variables. It
can be obtained by plotting βˆ(zj) against zj for each partitioning variable j = 1, . . . , J .
2.5. Variable importance
The variable importance for the random forest is computed based on the tree log-likelihoods.
For a given forest computed with T trees the log-likelihood is computed as follows:
• Select the out-of-bag data Lct and determine the terminal node/subgroup to which each
observation i belongs to.
Seibold, Zeileis, Hothorn 7
• Compute the log-likelihood contribution of each observation i ∈ Lct based on the respec-
tive model in the terminal node/subgroup with parameters ϑˆ(zi).
• Compute the out-of-bag log-likelihood as the sum of the contributions
lt =
∑
i∈Lct
l((y,x)i, ϑˆ(zi)). (13)
To obtain the variable importance of a given variable zj , j = 1, . . . , J , the variable is per-
muted. The log-likelihood is computed as above, except that the column with information
about zj in the out-of-bag data is replaced by the permuted zj . We denote the log-likelihood
of tree t with variable zj permuted by l
(j)
t . The variable importance is then
VIj =
1
T
T∑
t=1
[
lt − l(j)t
]
. (14)
If the variable importance is high the variable is an important predictive and/or prognostic
factor. Note that due to the absolute differences the variable importances may be negative.
3. Results
3.1. PRO-ACT data
The Pooled Open Access Clinical Trials (PRO-ACT, https://nctu.partners.org/ProACT)
database contains longitudinal data of ALS patients that participated in one of 16 phase
II and III trials and one observational study. It is a project initiated by the non-profit
organisation Prize4Life (http://www.prize4life.org/) to enhance knowledge about ALS.
It contains information on a broad variety of patient characteristics, such as vital signs, the
patient’s and family’s history, and treatment information. Identification criteria, such as
study centres, are not included in the database. Also collected are the survival time and
the ALS functional rating scale (ALSFRS), which is a score measuring the patients ability
of living a normal life (Brooks et al. 1996). The ALSFRS is a sum-score of ten items, each
of which ranges between zero and four, where zero represents complete inability and four
represents normal ability. The items are speech, salivation, swallowing, hand-writing, cutting
food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes,
walking, climbing stairs, and breathing. As outcomes in the study we used both the survival
time (denoted by survival) and the ALSFRS six months after treatment start (denoted by
ALSFRS6) and identified patient characteristics that influence the effect of Riluzole on these
outcomes. For the two outcome variables, we obtained two different data sets. We only
included observations that contain information on the respective outcome variable and only
patient characteristics that have fewer than 50% missing values. The survival time data set
contains 3306 observations and 18 patient characteristics. The ALSFRS data set contains
2534 observations and 57 patient characteristics.
Tables 1 and 2 show the estimates including standard errors obtained from the base model
for each outcome. For the ALSFRS this base model is given by
E
(
ALSFRS6
ALSFRS0
∣∣∣∣X = x) = E(ALSFRS6|X = x)ALSFRS0 = exp{α+ βxA}, (15)
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Table 1: ALSFRS base model (Gaussian generalised linear model with log-link and offset).
Given are the parameter estimates, their standard error and the Wald confidence interval.
Estimate Std.Error 2.5 % 97.5 %
α −0.1595 0.0065 −0.1722 −0.1468
β 0.0091 0.0077 −0.0060 0.0242
Table 2: Survival time base model (Weibull model). Given are the parameter estimates, their
standard error and the Wald confidence interval.
Estimate Std.Error 2.5 % 97.5 %
α1 6.7070 0.0323 6.6437 6.7703
β 0.1073 0.0387 0.0314 0.1832
log(α2) −0.5833 0.0271 −0.6364 −0.5302
which represents a Gaussian generalised linear model with log-link and offset log(ALSFRS0)
where ALSFRS0 is the ALSFRS that was measured at the time of treatment start. The base
model for the survival time is given by the Weibull model
P(T ≤ survival|X = x) = F
(
log(survival)− α1 − βxA
α2
)
, (16)
where F is the cumulative distribution function of the Gompertz distribution. Note that the
Weibull model has a scale parameter in addition to the intercept, so that both α1 and α2
control the appearance of the baseline hazard. In the notation of Equation 4, this leads to
ϑ = (α1, α2, β)
>.
3.2. Personalised models
We computed personalised models for all observations in the respective training data, which
were used to obtain the random forest. The distribution of parameter estimates in the per-
sonalised models is given in Figure 1 for the ALSFRS and in Figure 2 for the survival time.
Figure 1 shows that all patients are predicted to have a positive Riluzole effect, i.e. for all
patients taking Riluzole, a higher ALSFRS is achieved compared to those not taking Riluzole.
However, there is a variability in the treatment effects, and the distribution of the treatment
effect is bimodal (as is the distribution of the intercept). The treatment effect estimated from
the base model is between the two modes. The lowest treatment effect a person in this data
set is predicted to have is 0.0027.
For the survival time, the lowest predicted treatment effect is 0.0717. However, the value of
the treatment effect in the personalised survival models cannot be interpreted in isolation; its
meaning depends on the shape of the baseline hazard, i.e. on α1 and α2. Instead of depicting
the densities of the two baseline hazard parameters, in Figure 2 we show the baseline hazard
curves. The baseline hazard varies for different patients and there is a gap in the middle. The
baseline hazard estimated from the base model lies close to that gap.
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Figure 1: Kernel density estimates of the personalised parameter estimates for the ALSFRS.
Figure 2: Distribution of the personalised parameter estimates for the survival time. The
baseline hazard functions are given in the left panel; the kernel density estimate of the treat-
ment effect estimate are given in the right panel.
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Figure 3: Difference in log-likelihoods between forest and base model on the original data
(dashed lines; H1, the usual forest; H
α
1 the forest that splits based on α; H
β
1 the forest that
splits based on β) and on 50 samples simulated from the base model (density curve) for the
ALSFRS outcome.
From the personalised models, we obtained the “forest log-likelihoods” for both outcomes. For
the Gaussian GLM with log-link and offset, the log-likelihood contribution for observation i
is defined as
l
(
(ALSFRS6,ALSFRS0,x)i, ϑˆ(zi)
)
=
(
ALSFRS6i − exp
(
x>i ϑˆ(zi)
)
·ALSFRS0i
)2
(17)
with xi = (1, xAi)
> and ϑˆ(zi) = (αˆ(zi), βˆ(zi))>. For the Weibull model the log-likelihood
contribution for observation i is
l
(
(survival,x)i, ϑˆ(zi)
)
= δi log(αˆ2(zi))− δi survivali − x
>
i ϑˆ
∗
(zi)
αˆ2(zi)
+ exp
(
survivali − x>i ϑˆ
∗
(zi)
αˆ2(zi)
)
(18)
with xi = (1, xiA)
>, ϑˆ
∗
(zi) = (αˆ1(zi), βˆ(zi))
> and δi as the censoring indicator.
As can be seen in Figures 3 and 4 the forest log-likelihoods are higher than the log-likelihoods
of the base models for both the ALSFRS and the survival time. The figures show the difference
in log-likelihood between the forest and the corresponding base model. To show that this
difference is not due to overfitting, we drew 50 samples from the base models, i.e. 50 parametric
bootstrap samples for which the assumption holds that the intercept (or baseline hazard) and
treatment effect are the same for all patients. ALSFRS values are drawn from a normal
distribution truncated at zero to assure positivity. (The effect of truncation is virtually
negligible; only two observations had a truncation probability of more than 1%.) The survival
times are drawn from a Weibull distribution censored at the originally observed censoring
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Figure 4: Difference in log-likelihoods between forest and base model on the original data
(dashed lines; H1, the usual forest; H
α
1 the forest that splits based on α; H
β
1 the forest that
splits based on β) and on 50 samples simulated from the base model (density curve) for the
survival outcome.
times (if exceeded). The difference in log-likelihoods for both ALSFRS and survival time are
distributed close to zero, with a slight shift to the right, for the parametric bootstrap samples.
The large difference in the ALS data supports the assumption that the base models are not
ideal and personalised models are meaningful (the respective p-values are both zero). To
approximately check the sub-hypotheses given in equation 11 and 12, we also computed log-
likelihoods of the two forests that split only with respect to one of the partial score functions
– either intercept (or baseline hazard) or treatment effect. For the ALSFRS, both the forest
under Hα1 (computed with only splitting based on the partial score function with respect to
the intercept α), as well as the forest under Hβ1 (computed with only splitting based on partial
score function with respect to the treatment effect β), greatly improved compared to the base
model. The difference in log-likelihood between the forest under Hα1 and the base model is
even greater than between the original forest (H1) and the base model. For the survival time,
the log-likelihoods of the original forest and the forest under Hα1 (based on splits in the partial
score function with respect to the baseline hazard) are very close to each other. Splitting only
based on the partial score function with respect to the treatment effect (Hβ1 ) already improves
the log-likelihood but not as much as splitting based on both intercept and treatment effect
(H1). The good performance of the forests under H
α
1 indicate that (1) there are no predictive
patient characteristics, (2) all predictive patient characteristics are also prognostic, or (3) the
predictive nature of the predictive patient characteristics are so strong that it has enough
impact on the structure of the partial score function with respect to α.
3.3. Dependence plots
The dependence plots as shown in Figures 5 and 6 can be obtained for any partitioning
variable. Here we show the dependence plots for the four variables with the highest variable
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(a) Dependence plot for the time in days between
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Figure 5: Dependence plots for the four patient characteristics with the highest variable
importance from the ALSFRS forest.
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Figure 6: Dependence plots for the four patient characteristics with the highest variable
importance from the survival time forest.
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importance (see Section 3.4). For continuous variables, such as age, we show a scatter plot,
as before. For categorical variables, such as the variable weakness, which indicates whether
a patient suffers from muscle weakness (yes/no), boxplots giving the variation of β(z) and a
square representing β¯(z), i.e. the mean, are a meaningful way of representing the dependence
between treatment effect and the given variable.
The most obvious pattern of the four graphs in Figure 5 is shown in Subfigure 5d, in which the
personalised treatment effects are plotted against the forced vital capacity (FVC). Patients
with a low lung function (low FVC) are predicted to have a higher treatment effect than
those with better lung function. The graph shows a relatively clear cut at approximately
three litres. This indicates that FVC is a predictive factor. For the time between disease
onset and treatment start, the pattern is less clear. Patients with a short as well as those
with a long time between disease onset and treatment start seem to benefit most. Also for
the creatinine value, which indicates kidney function, only weak patterns are observed. The
phosphorus balance is slightly negatively associated with the treatment effect.
For the survival time, plotting only the treatment effect against a variable is not meaningful
since the interpretation of the treatment effect depends on the shape of the baseline hazard.
Therefore, we took a different approach in this case and show on the y-axis the difference
in median survival between treatment and control intake. For example, a value of 70 means
that based on the personalised model of this patient, the median survival is prolonged by
70 days if the patient takes Riluzole. The difference in median survival is denoted by ∆0.5.
Any other quantile could be used as well since from the Weibull model, information on the
entire estimated distribution in the two treatment groups is obtained. Taking the difference
in medians makes sense because it is a measure on the scale of the outcome, just as the
treatment effect in a linear model, which is the difference in means. The shape of ∆0.5 when
plotted against age shows a strong pattern that indicates that age is a predictive factor (see
Figure 6). The treatment efficacy increases with age until about 55 years and then flattens
The difference in median survival slightly increases with the days between disease onset and
start of treatment in the beginning, but decreases again after about 1000 days. Patients who
suffer from weakness have a greater variance in their benefit from Riluzole. Tall patients are
predicted to benefit little on average.
3.4. Variable importance
Figures 7 and 8 show the variable importance of each split variable. Figure 7 suggests that
the time between disease onset and start of treatment plays the most important role for the
personalised models. The time between disease onset and start of treatment, the forced vital
capacity (FVC), and the phosphorus balance have been shown to be the most important
variables for stratified models (Seibold et al. 2015) which is underlined by this analysis.
The time between disease onset and start of treatment contains information on the state of
disease progression for patients in the trial. If the disease onset and the start of treatment
are far apart, the patient is likely to have a slow progression (Hothorn and Jung 2014).
Also Riluzole has been shown to not be effective when the disease is already far progressed
(European Medicines Agency 2012). Thus it is not surprising that this variable is selected as
an important variable.
For the Riluzole effect on the survival time the patient’s age and again the time between
onset and treatment start play a role. Both variables have been identified before (Seibold
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Figure 7: Variable importances of all split variables used for the ALSFRS forest.
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Figure 8: Variable importances of all split variables used for the survival time forest.
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et al. 2015) as important factors for survival time.
4. Discussion
Model-based forests can find important predictive and prognostic patient characteristics and
– more importantly – via the personalised models provide the possibility to predict the treat-
ment effect of a future patient. Through analysis of the PRO-ACT data and simulations
(see appendix B), we showed that personalised models can perform better than the standard
global model if there are differences in treatment effect between patients. If there is no dif-
ference, the performance of the methods is about the same. These results allow a shift from
standardised medicine back to personalised medicine, but this time in a controlled way by
using statistical principles.
The presented methods are based on tree-based subgroup analyses but go a step further. Not
only are subgroups identified and the treatment effect within each group estimated, but many
slightly varying trees are used to retrieve a measure of similarity between patients. On this
basis, a model is computed in which more similar patients are weighted higher. The person-
alised models provide point estimates for the treatment effect. When the individual treatment
effects are plotted against patient characteristics researchers can determine on whether the
patient characteristics are predictive factors and in what way the patient characteristics and
the treatment effect are interacting. For ALS patients, the FVC value was predictive on the
ALSFRS, and the patient’s age and height were predictive on survival. The next step would
be to generate hypotheses from these findings and plan a study to test these. Our method of-
fers a promising means of providing individual treatment effect predictions and can be applied
to any clinical trial data where baseline patient characteristics are available.
All results were obtained solely using open-source implementation software (see Section 5),
which provides easy access to the methods.
5. Computational details
The code for data preprocessing of the PRO-ACT data is available in the TH.data package
(Hothorn 2014). The source code for the full analyses is available on https://github.com/
HeidiSeibold/personalised_medicine. Implementation of all methods discussed in this
paper are based on the R partykit package (Hothorn and Zeileis 2015, version 1.0-2). Other
R packages used were sandwich (Zeileis 2004, 2006, 2.3-3), survival (Therneau 2015, 2.38-
1), eha (Brostro¨m 2014, 2.4-2) and ggplot2 (Wickham 2009, 2.0.0). All computations were
conducted in the R system for statistical computing (R Core Team 2016, version 3.2.0).
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A. Split algorithm in detail
In the following, the split algorithm in model-based recursive partitioning is explained. The
split procedure starts with all N data points. In nodes other than the root node, the size of
the data set depends on the previous splits. For notational simplicity, we describe the split
procedure in the root node, i.e. for patients i = 1, . . . , N .
• Compute prespecified (parametric) modelM((Y,X),ϑ). Estimate ϑˆ by maximising the
log-likelihood
ϑˆ = argmax
ϑ
l((Y,X),ϑ)
or equivalently by solving
N∑
i=1
s((y,x)i,ϑ) = 0
for ϑ.
• Compute associated empirical estimating function (residuals)
s =

sαˆ((y,x)1, ϑˆ) sβˆ((y,x)1, ϑˆ)
sαˆ((y,x)2, ϑˆ) sβˆ((y,x)2, ϑˆ)
...
...
sαˆ((y,x)N , ϑˆ) sβˆ((y,x)N , ϑˆ)

• Perform tests of independence between residuals (partial score vectors) sαˆ as well as sβˆ
and partitioning variables Zj .
Hα,j0 : sαˆ((Y,X), ϑˆ) ⊥ Zj
Hβ,j0 : sβˆ((Y,X), ϑˆ) ⊥ Zj j = 1, . . . , J
For the tests, we use permutation testing with the linear statistic
Tj =
∑
i∈Bb
gj(Zji) · si
The transformation function g depends on the scale of the variable Zj . If Zj is numeric
then gj(zji) = zji. If Zj is categorical with K categories then gj(zji) = eK(zji) =
(I(zji = 1), . . . , I(zji = K)), i.e., gj is the unit vector of length K, where the element,
that corresponds to the value of zji, is one. If there are missing values in Zj the
observations are excluded from the sum so that we actually sum over all observations
i ∈ Bb, except for the observations in Bb, where Zj is missing. The standardised test
statistic is the Pearson correlation coefficient
c(tj , µj ,Σj) =
∣∣∣∣∣(tj − µj)√(Σj)
∣∣∣∣∣
if Zj is numeric and otherwise
c(tj , µj ,Σj) = max
k=1,...,K
∣∣∣∣∣(tj − µj)k√(Σj)kk
∣∣∣∣∣ .
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The conditional expectation µj and covariance Σj can be derived as in Strasser and
Weber (1999). The smallest p-value corresponds to the largest discrepancy from the
model assumption, that intercept and treatment parameter are the same for all patients
in the given node/subgroup.
• If any Bonferroni adjusted p-value is lower than the significance level, select the par-
titioning variable Zj∗ that has the highest association (lowest p-value) to any of the
residuals relevant for the split.
• Select as split point the point that results in the largest discrepancy between score
functions in the two resulting subgroups. The discrepancy can be measured by the
linear statistic
T kj∗ =
∑
i∈B1k
si,
where B1k here is the first of the two new subgroups that are defined by splitting in
split point k of variable Zj∗. The split point is then chosen as follows:
k∗ = argmin
k
c(tkj∗, µ
k
j∗,Σ
k
j∗).
B. Empirical evaluation
To check whether the proposed method can recover smooth treatment effect functions, we
evaluated its performance on artificial data. To do so, we simulated data from a normal linear
regression model. We simulated ten correlated patient characteristics, where only one is in
a non-linear interaction with the treatment. In the following, we compare the log-likelihood
of our method to the log-likelihood of the true underlying model and the naive model that
assumes an overall applicable treatment effect (Section B.1) and show the predicted treatment
effects in dependence plots (Section B.2) and the variable importances of the true predictive
factor and the noise variables (Section B.3).
We simulated 600 patients, half of which were treated (xA = 1) and half of which were
untreated (xA = 0). The ten partitioning variables Z are normally distributed
Z ∼ N10(0,ΣZ) (19)
and correlated with the covariance matrix
ΣZ =

1 0.2 · · · 0.2
0.2 1 · · · 0.2
...
...
. . .
...
0.2 0.2 · · · 1
 .
The primary outcome depends on treatment and partitioning variables as follows
Y |X = x,Z = z ∼ N (1.9 + 0.2 · xA + 3 · cos(z1) · xA, 1). (20)
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Figure 9: True treatment effect in given simulated data.
In this example the true model parameters are defined as follows:
α(z) = 1.9 (21)
β(z) = 0.2 + 0.3 · cos(z1).
This means that the treatment effect depends on the value of z1 and this dependency has the
form of a cosinus function (see Figure 9).
B.1. Comparison of models by comparing the log-likelihood
To compare our method with (i) a correctly specified model taking into account the main
effects of xA and cos(z1) as well as the interaction of xA and cos(z1) and (ii) a simple linear
model including only the treatment xA as a covariate, we drew 100 learning samples and 100
test samples using the data simulation procedure explained above and computed the out-of-
sample log-likelihoods (i.e. based on the test data) for the models after applying them to each
of the 100 learning data sets. The log-likelihood contributions
l
(
(y,x)i, ϑˆ(zi)
)
=
(
yi − x>i ϑˆ(zi)
)2
(22)
with xi = (1, xiA)
> and ϑˆ(zi) = (αˆ(zi), βˆ(zi))> are taken from the personalised models
of our method (see Section 2.5). Note that for the simple linear model the log-likelihood
contributions are defined as above, but only with constant parameters, for the fully specified
model xi = (1, xA, cos(z1), xA · cos(z1))> and ϑˆ = (αˆ, βˆA, βˆcos(z1), βˆA,cos(z1))>.
The log-likelihoods of our method are higher than the log-likelihoods of the simple and in-
correct linear model and lower than the log-likelihoods of the correctly specified model (Fig-
ure 10). Therefore, we conclude that our method performs reasonably well.
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Figure 10: Out-of-sample log-likelihoods obtained from the three models. Each line represents
one simulated data set.
B.2. Dependence plots
For the same 100 simulated test data sets as above, we obtained the dependence plots. Figure
11 shows two dependence plots in which all 100 simulations are combined by layering them
on top of each other. The dependence plot of partitioning variable z1 (Figure 11a) shows a
curve that is fairly similar to that of Figure 9, except that the effect is shrunken towards zero.
Note that with a larger sample or differently tuned parameters (e.g. larger trees), one could
get better results for the extreme treatment effects. As expected, for partitioning variables
z2 to z10, there is only random fluctuation around zero (see as an example Figure 11b, which
shows the dependence plot for z2).
B.3. Variable importance
Variable importances for one simulated data set are shown in Figure 12. As expected, par-
titioning variable z1 is the only variable with a clearly positive variable importance. Even
though all partitioning variables are correlated, the method was able to distinguish between
the correlation and predictive effect.
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(a) Dependence plot for z1. (b) Dependence plot for z2
Figure 11: Joint dependence plots of all 100 simulations.
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Figure 12: Variable importances of the predictive factor z1 and noise variables z2 to z10.
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